Medtronic gets FDA approval for Brainsense device

In Parkinson’s fight, Medtronic’s first-in-the-world adaptive therapy feature wins FDA approval
After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive technology personalizing treatment of Parkinson’s symptoms using advanced stimulation deep in the brain.
FDA approves Medtronic device for Parkinson's treatment
The FDA has approved Medtronic's Brainsense Adaptive deep brain stimulation for patients with Parkinson's disease. The technology is designed to adjust therapy in real time based on a patient's brain activity, potentially improving symptom control, according to a Feb. 24 news release from the company.
US FDA approves Medtronic's medical device for Parkinson's disease
The U.S. Food and Drug Administration has approved Medtronic's deep brain stimulation system for use in patients with Parkinson's disease, the medical device maker said on Monday.
Medtronic gets FDA approval for Brainsense device in Parkinson's patients
Medtronic said Monday the U.S. Food and Drug Administration has approved an adaptive brain-stimulation device as a treatment for people with Parkinson's disease, a major milestone for the technology.
FDA approves Medtronic’s brain stimulation system for Parkinson’s
The FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.
Medtronic wins first FDA nod for adaptive DBS for Parkinson’s
(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.
Medtronic's deep brain stimulation system for Parkinson's disease wins FDA nod
Medtronic (NYSE:MDT) has won FDA approval for a deep brain stimulation system for Parkinson’s disease. The approval is for BrainSense Adaptive deep brain stimulation (DBS)and BrainSense Electrode Identifier.
Medtronic explores options to optimize manufacturing operations amid Trump's tariff threats
Medical device maker Medtronic is looking at options to modify its global manufacturing footprint as part of efforts to ...
Medtronic evaluating manufacturing footprint amid higher tariffs: report
Medtronic (NYSE:MDT), which has operations worldwide, is reportedly looking at adjusting its manufacturing footprint amid ...
Medical Design and Outsourcing5h
A Medtronic engineer shares lessons from the adaptive deep brain stimulation project
The biggest technical challenge for adaptive deep brain stimulation (aDBS) is how small brain signals are, Medtronic's Scott ...
Why Medtronic Stock Is Sinking Today
Shares of Medtronic ( MDT -6.63%) were sinking 7.3% as of 11:21 a.m. ET on Tuesday. The decline came after the medical device ...
Medtronic Stock Slumps as Sales Miss Estimates
The revenue miss came as sales at Medtronic's Medical Surgical division declined 1.9% to $2.07 billion. The company pointed ...
devdiscourse2h
Health Sector Headlines: From Tariff Talk to Drug Pricing Dynamics
The latest health news reveals Medtronic's strategic response to U.S. tariffs, WHO's concerns on West Bank violence, mystery ...
Is Medtronic Stock a Buy?
Medtronic's stock is probably not a jaw-dropping bargain at these prices, but it's an excellent business at a reasonable value. It's safe to call Medtronic a solid buy, especially if you're a ...